Global Cancer Biomarkers Market 2022-2028

Description

List of Tables

Global Cancer Biomarker Market Size, Share & Trends Analysis Report by Biomarker Type (Genetic Biomarker and Protein Biomarker), by Cancer Type (Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, and Cervical Cancer), by Application (Drug Discovery & Development, Diagnosis, Risk Assessment, and Prognostics), and by Profiling Technology (Omics Technology, Immunoassays, Cytogenetics, and Bioinformatics) Forecast Period (2022-2028)

The global cancer biomarker market is anticipated to grow at a substantial CAGR of 12.4% during the forecast period.The rising global incidence of cancer and higher acceptance of cancer treatments in developing countries, the healthcare paradigm change from illness diagnosis to risk assessment or early diagnosis, and the increased use of biomarkers in therapeutic development. According to the American Cancer Societyofthe US, in 2020, around 276,480 new cases of invasive breast cancers were diagnosed in women 2,620 cases diagnosed in men; and an additional 48,530 cases of ductal carcinoma in situ (DCIS) diagnosed in women An estimated 42,690 breast cancer deaths (42,170 women, 520 men) occurred in 2020.

However, the high cost of drug development, the threat of failure associated with cancer treatment, and unregulated government regulations and reimbursement policies hamper the cancer biomarkers market growth. In contrast, advancements incancer research and significant unmet need for cancer diagnosis are anticipated to provide new opportunities for the cancer biomarkers market.

The global cancer biomarker market is segmented based on the biomarker type, cancer type, application, and profiling technology. Based on the biomarker type, the market is segmented into genetic biomarkers and protein biomarkers. Based on, the cancer type, the market is sub-segmented into lung cancer, prostate cancer, breast cancer, colorectal cancer, and cervical cancer. Based on the application, the market is segmented into drug discovery and development, diagnosis, risk assessment, and prognostics. Further, based on profiling technology, the market is sub-segmented into omics technology, immunoassays, cytogenetics, and bioinformatics. The above-mentioned segments can be customized as per the requirements. Among the cancer type, the lung cancer segment is expected to grow at a remarkable pace during the forecast period. Lung cancer is the second most common type of cancer and the leading cause of deathcaused by the uncontrollable proliferation of aberrant cells in one or both lungs. Cigarette smoking is by far the most important risk factor for lung cancer, with approximately 80% of lung cancer deaths in the US still caused by smoking. According to the American Cancer Society, in 2020, an estimated 228,820 new cases of lung cancer will be diagnosed in the US and 135,720 people will die from the disease.

Geographically the global cancer biomarker market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Europe is expected to cater to the fastest-growthregion in the market owing to the rising number of cases of cancer. The major factors contributing to the European market are the high prevalence of cancerand high per capita healthcare expenditure. Furthermore, the growing focus of pharmaceutical companies on this region, combined with the rising alertness of biomarker-based diagnosis, is one of the high influence growth drivers. For instance, in November 2019, Hitachi and Centre Leon Berard cancer center in France promoted R&D aimed at improving the efficiency of diagnosis and treatment of cancer and established a new research laboratory called Hitachi Lyon Lab.

The major players that servethe growth of the global cancer biomarker market include Abbott Laboratories Inc., Bio-Rad Laboratories, Inc., Danaher Corp., F. Hoffmann-La Roche Ltd., Illumina, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., QIAGEN GmbH, Thermo Fisher Scientific Inc., and many others. The players operating in the market adopt various strategies such as technology development, product launch, merger, and acquisition for gaining asustainable position in the market that further propels the growth of the market. For instance, in April 2021, F. Hoffmann-La Roche Ltd. launched Elecsys Anti-p53 immunoassay to aid the diagnosis of various cancer types.

Research Methodology

The market study of the global cancer biomarker market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.
Whitepapers, research papers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of the market sizeand the intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Cancer biomarker Market Research and Analysis by Biomarker type.

2. Global Cancer biomarker Market Research and Analysis by Cancer Type.

3. Global Cancer biomarker Market Research and Analysis by Application.

4. Global Cancer biomarker Market Research and Analysis by Profiling Technology.

The Report Covers

Comprehensive research methodology of the global cancer biomarker market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global cancer biomarker market.
Insights about market determinants that are stimulating the global cancer biomarker market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: BIOT-0409

Category- Biotechnology

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Cancer Biomarker Market
Recovery Scenario of Global Cancer Biomarker Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. ByRegion

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
3.2. Abbott Laboratories Inc.
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. F. Hoffmann-La Roche Ltd.
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Merck and Co., Inc.
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Novartis AG
- 3.5.1. Overview
- 3.5.2. Financial Analysis
- 3.5.3. SWOT Analysis
- 3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of COVID-19 on Key Players

4. Market Segmentation

4.1. Global Cancer Biomarker Market by Biomarker Type
- 4.1.1. Genetic Biomarker
- 4.1.2. Protein Biomarker
4.2. Global Cancer Biomarker Market by Cancer Type
- 4.2.1. Lung Cancer
- 4.2.2. Prostate Cancer
- 4.2.3. Breast Cancer
- 4.2.4. Colorectal Cancer
- 4.2.5. Cervical Cancer
- 4.2.6. Other
4.3. Global Cancer Biomarker Market by Application
- 4.3.1. Drug Discovery and development
- 4.3.2. Diagnosis
- 4.3.3. Risk Assessment
- 4.3.4. Prognostics
4.4. Global Cancer Biomarker Market by Profiling Technology
- 4.4.1. Omnic Technology
- 4.4.2. Immunoassays
- 4.4.3. Cytogenetics
- 4.4.4. Bioinformatics

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Abcodia Ltd.
6.2. Agendia N.V.
6.3. Agilent Technologies, Inc.
6.4. Astellas Pharma Inc.,
6.5. Becton, Dickson, and Co.
6.6. Biodesix, Inc.
6.7. BioMerieux S.A.
6.8. Bio-Rad Laboratories, Inc.
6.9. Danaher Corp.
6.10. Diazyme Laboratories Inc.
6.11. Hologic, Inc.
6.12. Illumina, Inc.
6.13. Myriad Genetics, Inc.
6.14. NeoGenomics, Inc.
6.15. Pfizer Inc.
6.16. QIAGEN GmbH
6.17. Thermo Fisher Scientific Inc.